Choi Peter, Farouk Mourad, Manamley Nick, Addison Janet
Department of Nephrology, John Hunter Hospital, Lookout Road, New Lambton Heights, NSW, 2305, Australia,
Adv Ther. 2013 Nov;30(11):1007-17. doi: 10.1007/s12325-013-0063-y. Epub 2013 Oct 31.
There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo.
Eligible patients had received hemodialysis for ≥ 12 months and DA for ≥ 7 months. Data were collected from 7 months before until 7 months after switching treatment. DCR was calculated for patients with Hb and ESA data available in both evaluation periods (EP; Months 1 and 2 were defined as the pre-switch EP, and Months 6 and 7 as the post-switch EP). Red blood cell transfusions pre- and post-switch were quantified.
Of 302 patients enrolled, 206 had data available for DCR analysis. The geometric mean DCR was 1.17 (95% CI 1.05, 1.29). Regression analysis indicated a non-linear relationship between pre- and post-switch ESA doses; DCR decreased with increasing pre-switch DA dose. The geometric mean weekly ESA doses were 24.1 μg DA in the pre-switch EP and 28.6 μg PEG-Epo in the post-switch EP. Mean Hb was 11.5 g/dL in the pre-switch EP and 11.4 g/dL in the post-switch EP. There were 16 transfusions and 34 units transfused in the pre-switch period, versus 48 transfusions and 95 units transfused post-switch. Excluding patients receiving a transfusion within 90 days of or during either EP, the DCR was 1.21 (95% CI 1.09, 1.35).
In these hemodialysis patients switched from DA to PEG-Epo the DCR was 1.17 and 1.21 after accounting for the effect of transfusions. The number of transfusions and units transfused increased approximately threefold from the pre-switch to the post-switch period.
在干预性临床研究方案之外,关于将促红细胞生成素刺激剂(ESA)治疗从达比加群酯(DA)转换为甲氧基聚乙二醇促红细胞生成素β(PEG-Epo)用于治疗慢性肾脏病(CKD)相关贫血的信息有限。AFFIRM(阿法达贝泊汀相对于米内网的疗效)是一项回顾性、多中心观察性研究,旨在估计欧洲血液透析患者从DA转换为PEG-Epo治疗时的总体平均维持剂量转换率[DCR;两个评估期内达到可比血红蛋白水平(Hb)的剂量比]。
符合条件的患者接受血液透析≥12个月且接受DA治疗≥7个月。收集从转换治疗前7个月到转换治疗后7个月的数据。对两个评估期(EP;第1个月和第2个月定义为转换前EP,第6个月和第7个月定义为转换后EP)均有Hb和ESA数据的患者计算DCR。对转换前后的红细胞输注量进行量化。
在纳入的302例患者中,206例有可用数据进行DCR分析。几何平均DCR为1.17(95%CI 1.05,1.29)。回归分析表明转换前后ESA剂量之间存在非线性关系;DCR随转换前DA剂量增加而降低。转换前EP中每周ESA平均剂量为24.1μg DA,转换后EP中为28.6μg PEG-Epo。转换前EP中平均Hb为11.5g/dL,转换后EP中为11.4g/dL。转换前有16次输血,输注34单位,转换后有48次输血,输注95单位。排除在任何一个EP期间或转换前90天内接受输血的患者后,DCR为1.21(95%CI 1.09,1.35)。
在这些从DA转换为PEG-Epo的血液透析患者中,考虑输血影响后DCR为1.17和1.21。从转换前到转换后,输血次数和输注单位数增加了约三倍。